Swedencare's Q2: North American stumble masks Europe-led momentum — and an Amazon redemption arc
Organic growth of 7% landed under the double-digit guide on big-box delays and a distributor merger, but Europe (+19%), Production (+25%) and a rebounding China set up a stronger H2.
SECARE.ST · Earnings Call · 2026-07-22
After a spring spent promising an improved trajectory, Swedencare's Q2 landed with a thud in its largest market. Group organic growth of 7% — versus a communicated double-digit expectation and "the same level as we were in Q2 last year" per CFO Jenny Graflind — was dragged down by North America's -3%. But peel back the layer and the quarter is less a demand story and more a logistics-and-distribution story, with the real organic engines, Europe and Production, compounding at 19% and 25%. The question investors face: is this a one-off stumble or a pattern in delivery?
The North American miss — one-offs, or a habit?
North America's 55% of revenue declined 3% organically, driven by two specific events: a delayed Big Box launch delivery, and the merger of the two largest U.S. veterinary distributors pulling inventory levels down during the "discovery process." CEO Håkan Lagerberg was blunt about the former:
The major factor why we came in in minus territory was, as we've said, the private label launch delivery to a new big box customer was delayed because of substantial quality controls implemented by the customer, but performed by a third party just before ship-out.
When asked whether the group would have hit its target without the delay, Lagerberg's answer was terse: “It would've been double digit.” — Håkan Lagerberg, Chief Executive Officer · 2026-07-22 The shipment has since cleared (production approved by quarter-end, delivered in July), and management expects replenishment orders to flow through Q3 — explicitly guiding North America back to "high single digit or hopefully double-digit" growth.
But this is the second consecutive quarter where channel events have bitten. In the prior call, the same management team was contrite about Q4's cost overruns on marketing and a Walmart display campaign:
We definitely failed in Q4. And now we have to rebuild the trust. And the way to rebuild that trust is that we show a couple of quarters with improved margins and improved EBITDA, of course.
The distribution-merger inventory hit, meanwhile, is structural but time-bounded: Lagerberg noted a decision on the merger approval is expected in H2, with Veterinary partnerships inventory levels expected to rebuild in Q3 as sell-out of their product continues.
The Amazon redemption arc
If big-box delays are the headline, the enduring subplot is Amazon. This is a theme with real history — the Q4 call was almost entirely about MAP pricing, rogue sellers, display campaigns, and the distribution expansion that briefly broke MAP compliance. In February, Håkan said the transparency program would be "in full force by Q2":
“I would expect that the programs will have come into full force in Q2, not in Q1, but we will see improvements in Q1.” — Hakan Lagerberg, CEO · 2026-02-12
True to the timeline, Q2's message is one of stabilization: MAP violations "significantly reduced," the Buy Box and Best Seller badges restored on key products, and — per NaturVet CEO Geoff Granger — “over the last 60 days or so, we're now seeing steady consumption growth on Amazon.” — Geoff Granger, Chief Executive Officer · 2026-07-22 The cost, however, was visible in the quarter's external cost line: enhanced marketing around Amazon, including the timing shift of Prime Day into June (versus July last year), plus the effort to claw back badges.
“As I always say, as goes Amazon, kind of goes your total business.” — Geoff Granger, Chief Executive Officer · 2026-07-22
The strategic pivot under pet specialty is to defend the mature channel while scaling the food/drug/mass/club push — Walmart at 1,700+ locations, CVS at ~1,100, plus the private-label FDMC program. Walmart consumption still "lags original targets" per Granger, but he reports awareness and consideration now exceed competitor averages by 100 bps and usage by 200 bps after shifting marketing to full-funnel, hero-item-led activation.
Where growth actually lives
The offsetting story is genuinely strong. Europe grew 19% organically, now 25% of group revenue and "handling more than 90% of group internal manufacturing." Production grew 25%, powered by contract manufacturing and the Vetio North pharma ramp. China, an important highlight, saw Q2 sales exceed last year's full-year level (a ~SEK 8M order), and Lagerberg is exploring manufacturing partnerships to launch more brands there — a concrete step beyond Export markets' flagship ProDen PlaqueOff, which itself grew over 30%. The cat-specific ProDen PlaqueOff Creme was introduced at Interzoo and ships in Q3 — fulfilling the promise from the Q3 2025 call: “We will be introducing a very interesting product for cats early next year... cats and dental are a tricky issue to handle because of the finicky type of personalities that cats generally are.” — Hakan Lagerberg, CEO · 2025-10-22
Notably, this is the first quarter since 2019 without any acquired growth — Summit Vet has rolled into the organic base — making the 7% organic number a purer read on underlying demand than any quarter in six years.
Margin and the moving parts
Gross margin printed 61%, the best since 2020, though CFO Jenny Graflind cautions it was flattered by the inventory buildup tied to the delayed shipment: “I think 61% was exceptionally high due to the effect that the U.S. came in a lot lower than we expected.” — Jenny Graflind, Chief Financial Officer · 2026-07-22 The company is holding to its 58-59% full-year corridor, expecting the U.S. mix to weigh on the out quarters. Operational EBITDA margin came in at 19.3%, up 30 bps year-on-year but below expectations on the sales shortfall; net debt/EBITDA stepped to 3.1x, more a function of the upcoming Summit Vet earn-out and a SEK 44M dividend rather than operational cash burn. Management's guidance is unambiguous: “We expect profitability to improve in the second half of this year compared to the first half.” — Jenny Graflind, Chief Financial Officer · 2026-07-22
The bull case rests on the one-off nature of the North American miss, a now-cleared launch queue, and the compounding Europe/Production engine. The bear case is that two consecutive quarters of channel friction showing up as guide misses suggests execution risk is real, not rhetorical. With trust explicitly on the line, H2 is the tell.